126 related articles for article (PubMed ID: 34923575)
1. Validation analysis of the novel imaging-based prognostic radiomic signature in patients undergoing primary surgery for advanced high-grade serous ovarian cancer (HGSOC).
Fotopoulou C; Rockall A; Lu H; Lee P; Avesani G; Russo L; Petta F; Ataseven B; Waltering KU; Koch JA; Crum WR; Cunnea P; Heitz F; Harter P; Aboagye EO; du Bois A; Prader S
Br J Cancer; 2022 Apr; 126(7):1047-1054. PubMed ID: 34923575
[TBL] [Abstract][Full Text] [Related]
2. A Computed Tomography-Based Radiomic Prognostic Marker of Advanced High-Grade Serous Ovarian Cancer Recurrence: A Multicenter Study.
Wei W; Liu Z; Rong Y; Zhou B; Bai Y; Wei W; Wang S; Wang M; Guo Y; Tian J
Front Oncol; 2019; 9():255. PubMed ID: 31024855
[No Abstract] [Full Text] [Related]
3. Noninvasive prediction of residual disease for advanced high-grade serous ovarian carcinoma by MRI-based radiomic-clinical nomogram.
Li H; Zhang R; Li R; Xia W; Chen X; Zhang J; Cai S; Li Y; Zhao S; Qiang J; Peng W; Gu Y; Gao X
Eur Radiol; 2021 Oct; 31(10):7855-7864. PubMed ID: 33864139
[TBL] [Abstract][Full Text] [Related]
4. Deep learning provides a new computed tomography-based prognostic biomarker for recurrence prediction in high-grade serous ovarian cancer.
Wang S; Liu Z; Rong Y; Zhou B; Bai Y; Wei W; Wei W; Wang M; Guo Y; Tian J
Radiother Oncol; 2019 Mar; 132():171-177. PubMed ID: 30392780
[TBL] [Abstract][Full Text] [Related]
5. HOXA4/HOXB3 gene expression signature as a biomarker of recurrence in patients with high-grade serous ovarian cancer following primary cytoreductive surgery and first-line adjuvant chemotherapy.
Miller KR; Patel JN; Zhang Q; Norris EJ; Symanowski J; Michener C; Sehouli J; Braicu I; Destephanis DD; Sutker AP; Jones W; Livasy CA; Biscotti C; Ganapathi RN; Tait DL; Ganapathi MK
Gynecol Oncol; 2018 Apr; 149(1):155-162. PubMed ID: 29402501
[TBL] [Abstract][Full Text] [Related]
6. Development of MRI-Based Radiomics Model to Predict the Risk of Recurrence in Patients With Advanced High-Grade Serous Ovarian Carcinoma.
Li HM; Gong J; Li RM; Xiao ZB; Qiang JW; Peng WJ; Gu YJ
AJR Am J Roentgenol; 2021 Sep; 217(3):664-675. PubMed ID: 34259544
[No Abstract] [Full Text] [Related]
7. Radiomics of high-grade serous ovarian cancer: association between quantitative CT features, residual tumour and disease progression within 12 months.
Rizzo S; Botta F; Raimondi S; Origgi D; Buscarino V; Colarieti A; Tomao F; Aletti G; Zanagnolo V; Del Grande M; Colombo N; Bellomi M
Eur Radiol; 2018 Nov; 28(11):4849-4859. PubMed ID: 29737390
[TBL] [Abstract][Full Text] [Related]
8. Clinical factors associated with prognosis in low-grade serous ovarian carcinoma: experiences at two large academic institutions in Korea and Taiwan.
Kang JH; Lai YL; Cheng WF; Kim HS; Kuo KT; Chen YL; Lee YY
Sci Rep; 2020 Nov; 10(1):20012. PubMed ID: 33203969
[TBL] [Abstract][Full Text] [Related]
9. Development and validation of prognostic gene signature for basal-like breast cancer and high-grade serous ovarian cancer.
Zhang Y; Liu J; Raj-Kumar PK; Sturtz LA; Praveen-Kumar A; Yang HH; Lee MP; Fantacone-Campbell JL; Hooke JA; Kovatich AJ; Shriver CD; Hu H
Breast Cancer Res Treat; 2020 Dec; 184(3):689-698. PubMed ID: 32880016
[TBL] [Abstract][Full Text] [Related]
10. Positron emission tomography (PET) and magnetic resonance imaging (MRI) for assessing tumour resectability in advanced epithelial ovarian/fallopian tube/primary peritoneal cancer.
Roze JF; Hoogendam JP; van de Wetering FT; Spijker R; Verleye L; Vlayen J; Veldhuis WB; Scholten RJ; Zweemer RP
Cochrane Database Syst Rev; 2018 Oct; 10(10):CD012567. PubMed ID: 30298516
[TBL] [Abstract][Full Text] [Related]
11. Advanced low grade serous ovarian cancer: A retrospective analysis of surgical and chemotherapeutic management in two high volume oncological centers.
Di Lorenzo P; Conteduca V; Scarpi E; Adorni M; Multinu F; Garbi A; Betella I; Grassi T; Bianchi T; Di Martino G; Amadori A; Maniglio P; Strada I; Carinelli S; Jaconi M; Aletti G; Zanagnolo V; Maggioni A; Savelli L; De Giorgi U; Landoni F; Colombo N; Fruscio R
Front Oncol; 2022; 12():970918. PubMed ID: 36237308
[TBL] [Abstract][Full Text] [Related]
12. Primary debulking surgery versus primary neoadjuvant chemotherapy for high grade advanced stage ovarian cancer: comparison of survivals.
Kobal B; Noventa M; Cvjeticanin B; Barbic M; Meglic L; Herzog M; Bordi G; Vitagliano A; Saccardi C; Skof E
Radiol Oncol; 2018 Sep; 52(3):307-319. PubMed ID: 30210049
[TBL] [Abstract][Full Text] [Related]
13. Development and Validation of a Preoperative Magnetic Resonance Imaging Radiomics-Based Signature to Predict Axillary Lymph Node Metastasis and Disease-Free Survival in Patients With Early-Stage Breast Cancer.
Yu Y; Tan Y; Xie C; Hu Q; Ouyang J; Chen Y; Gu Y; Li A; Lu N; He Z; Yang Y; Chen K; Ma J; Li C; Ma M; Li X; Zhang R; Zhong H; Ou Q; Zhang Y; He Y; Li G; Wu Z; Su F; Song E; Yao H
JAMA Netw Open; 2020 Dec; 3(12):e2028086. PubMed ID: 33289845
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of supraclavicular lymphadenopathy in patients with high-grade serous ovarian cancer.
Cybulska P; Hayes SA; Spirtos A; Rafizadeh MJ; Filippova OT; Leitao M; Zivanovic O; Sonoda Y; Mueller J; Lakhman Y; Long K; Chi DS
Int J Gynecol Cancer; 2019 Nov; 29(9):1377-1380. PubMed ID: 31575614
[TBL] [Abstract][Full Text] [Related]
15. A novel classification of residual disease after interval debulking surgery for advanced-stage ovarian cancer to better distinguish oncologic outcome.
Manning-Geist BL; Hicks-Courant K; Gockley AA; Clark RM; Del Carmen MG; Growdon WB; Horowitz NS; Berkowitz RS; Muto MG; Worley MJ
Am J Obstet Gynecol; 2019 Oct; 221(4):326.e1-326.e7. PubMed ID: 31082382
[TBL] [Abstract][Full Text] [Related]
16. Prolonged interruption of chemotherapy in patients undergoing delayed debulking surgery for advanced high grade serous ovarian cancer is associated with a worse prognosis.
Searle G; Pounds R; Phillips A; Kehoe S; Balega J; Singh K; Yap J
Gynecol Oncol; 2020 Jul; 158(1):54-58. PubMed ID: 32345546
[TBL] [Abstract][Full Text] [Related]
17. Potential risk factors associated with prognosis of neoadjuvant chemotherapy followed by interval debulking surgery in stage IIIc-IV high-grade serous ovarian carcinoma patients.
Zhang J; Liu N; Zhang A; Bao X
J Obstet Gynaecol Res; 2018 Sep; 44(9):1808-1816. PubMed ID: 30019801
[TBL] [Abstract][Full Text] [Related]
18. Discovery of a biomarker candidate for surgical stratification in high-grade serous ovarian cancer.
Lu H; Cunnea P; Nixon K; Rinne N; Aboagye EO; Fotopoulou C
Br J Cancer; 2021 Mar; 124(7):1286-1293. PubMed ID: 33473167
[TBL] [Abstract][Full Text] [Related]
19. Impact of hemodynamic instability during cytoreductive surgery on survival in high-grade serous ovarian carcinoma.
Kim SI; Lee HC; Yoon HK; Kim HS; Chung HH; Kim JW; Park NH; Song YS; Lee M
BMC Cancer; 2022 Sep; 22(1):965. PubMed ID: 36085013
[TBL] [Abstract][Full Text] [Related]
20. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]